113 related articles for article (PubMed ID: 16941073)
1. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.
Liu Y; Wang Q; Kleinschmidt-DeMasters BK; Franzusoff A; Ng KY; Lillehei KO
J Neurooncol; 2007 Jan; 81(2):149-62. PubMed ID: 16941073
[TBL] [Abstract][Full Text] [Related]
2. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination.
Graf MR; Prins RM; Hawkins WT; Merchant RE
Cancer Immunol Immunother; 2002 Jun; 51(4):179-89. PubMed ID: 12012105
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization.
Corsini E; Gelati M; Calatozzolo C; Alessandri G; Frigerio S; De Francesco M; Poiesi C; Parati E; Croci D; Boiardi A; Salmaggi A
Cancer Immunol Immunother; 2004 Nov; 53(11):955-62. PubMed ID: 15449042
[TBL] [Abstract][Full Text] [Related]
5. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors.
Manome Y; Wen PY; Hershowitz A; Tanaka T; Rollins BJ; Kufe DW; Fine HA
Cancer Immunol Immunother; 1995 Oct; 41(4):227-35. PubMed ID: 7489565
[TBL] [Abstract][Full Text] [Related]
6. Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer.
Lee HK; Ji HJ; Shin SK; Koo J; Kim TH; Kim CW; Seong YH; Park JE; Choi KC
Cancer Immunol Immunother; 2022 Sep; 71(9):2213-2226. PubMed ID: 35099588
[TBL] [Abstract][Full Text] [Related]
7. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression.
Prins RM; Scott GP; Merchant RE; Graf MR
Cancer Immunol Immunother; 2002 Jun; 51(4):190-9. PubMed ID: 12012106
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model.
Ishikawa E; Tsuboi K; Takano S; Uchimura E; Nose T; Ohno T
Cancer Sci; 2004 Jan; 95(1):98-103. PubMed ID: 14720334
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses.
Ammons DT; Guth A; Rozental AJ; Kurihara J; Marolf AJ; Chow L; Griffin JF; Makii R; MacQuiddy B; Boss MK; Regan DP; Frank C; McGrath S; Packer RA; Dow S
Cancer Res Commun; 2022 Dec; 2(12):1657-1667. PubMed ID: 36644324
[TBL] [Abstract][Full Text] [Related]
10. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
[TBL] [Abstract][Full Text] [Related]
11. Antisense Oligonucleotides for Rapid Translation of Gene Therapy in Glioblastoma.
Desgraves JF; Mendez Valdez MJ; Chandar J; Gurses ME; Henderson L; Castro JR; Seetheram D; Ivan ME; Komotar RJ; Shah AH
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792022
[TBL] [Abstract][Full Text] [Related]
12. Nucleic acid immunotherapeutics and vaccines: A promising approach to glioblastoma multiforme treatment.
Dain L; Zhu G
Int J Pharm; 2023 May; 638():122924. PubMed ID: 37037396
[TBL] [Abstract][Full Text] [Related]
13. A Novel Recombinant Newcastle Disease Vaccine Improves Post-
Marcano VC; Cardenas-Garcia S; Diel DG; Antoniassi da Silva LH; Gogal RM; Miller PJ; Brown CC; Butt SL; Goraichuk IV; Dimitrov KM; Taylor TL; Williams-Coplin D; Olivier TL; Stanton JB; Afonso CL
Vaccines (Basel); 2021 Aug; 9(9):. PubMed ID: 34579191
[No Abstract] [Full Text] [Related]
14. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.
Le BT; Raguraman P; Kosbar TR; Fletcher S; Wilton SD; Veedu RN
Mol Ther Nucleic Acids; 2019 Mar; 14():142-157. PubMed ID: 30594893
[TBL] [Abstract][Full Text] [Related]
15. Novel vaccines for glioblastoma: clinical update and perspective.
Winograd EK; Ciesielski MJ; Fenstermaker RA
Immunotherapy; 2016 Nov; 8(11):1293-1308. PubMed ID: 27993092
[TBL] [Abstract][Full Text] [Related]
16. Immune-checkpoint blockade and active immunotherapy for glioma.
Ahn BJ; Pollack IF; Okada H
Cancers (Basel); 2013 Nov; 5(4):1379-412. PubMed ID: 24202450
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
18. Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
Otten J; Bokemeyer C; Fiedler W
J Oncol; 2010; 2010():317068. PubMed ID: 20490264
[TBL] [Abstract][Full Text] [Related]
19. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of diffuse gliomas: biological background, current status and future developments.
Grauer OM; Wesseling P; Adema GJ
Brain Pathol; 2009 Oct; 19(4):674-93. PubMed ID: 19744040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
